Merck’s Life Science business sector and Afrigen Biologics announced in July 2024 that they have entered a non-binding Memorandum of Understanding (MoU) to support the development of an mRNA vaccine technology platform. The collaboration will seek to advance manufacturing capabilities, scale up production, optimise processes, and provide troubleshooting expertise. Within the MoU, Merck will support Afrigen’s Centre of Excellence and training initiatives, intended to build mRNA production capacity in LMICs.
Technology transfer
Co-led by WHO and Medicines Patent Pool (MPP), the mRNA technology transfer programme will provide knowledge transfer to allow 15 recipient manufacturers to produce and release mRNA vaccines at scale to support clinical development, national/regional marketing authorisation and WHO prequalification, and sustainable supply to meet local and regional demand.
Merck describes itself as “one of the key players” driving mRNA technology forward. It brings a comprehensive approach involving mRNA expertise, tech-transfer proficiency, regulatory knowledge, and product portfolios streamline manufacturing and testing.
Combining expertise
Head of Commercial EMEA Process Solutions, Life Science business sector of Merck, Bert de Vet, hopes that by “leveraging our comprehensive chemical portfolio and custom production capabilities”, Merck will be able to “offer cutting-edge experience” to ensure a “seamless journey from research to production”.
“Our alliance with Afrigen for mRNA technology platform development echoes our commitment to fostering equitable access to life-saving therapies for global health.”
Professor Petro Terblanche, CEO of Afrigen, stated that the mRNA vaccine technology transfer hub is “well on its way to create a sustainable mRNA product innovation platform for public health benefit and pandemic preparedness”.
“The platform at Afrigen provides access to mRNA technology for 15 partners in LMICs and straddles the entire vaccine value chain from R&D to Good Manufacturing Practices (GMP) manufacturing. Following the launch of the programme in 2021, we have successfully developed mRNA vaccine technology R&D and production capabilities. Our progress has been accelerated by Merck’s technical expertise.”
Dr Ike James, Head of Technology Transfer at Medicines Patent Pool, commented that the mRNA technology transfer programme distinguishes itself through “exceptional collaboration among numerous partners, all dedicated to empowering LMICs to develop and manufacture the mRNA vaccines of the future”.
“Today’s MoU signing between Afrigen and Merck is a clear testament to this shared commitment and a significant step in this journey.”
For more from Professor Terblanche at the Congress in Barcelona this October, get your tickets here. Don’t forget to subscribe to our weekly newsletters here.
